The FDA approval and commercial rollout of Arbli is HUGE news, but the stock is stuck in a downtrend with both WMAs sloping down. The RSI is in the "meh" zone, not oversold enough for a real bounce. The market seems skeptical, waiting for those sales figures to actually hit. This is a classic "show me" story. I'm holding off until the technicals catch up to the headlines. #WaitAndSee

The stock of Scienture Holdings, Inc. (SCNX) saw a substantial decline throughout the trading sessions on March 18, 2025 moving from a strong bullish stance early in the day to a pronounced bearish trend. The stock opened at $3.04 but saw a sharp drop and ended at just $1.59. Despite several attempts to rally at different points, the stock failed to find a solid footing, dipping further in each successive session. The trading volume was significant during the bearish plunges, indicating a sell-off mentality among the investors. Now, the key focus would be on the established support level at around $1.58. Any further decline below this point could raise the stakes towards more bearish momentum. Moreover, the surges in trading volume coupled with the marked decline in price is a negative sign, suggesting that the stock may be oversold. Interestingly, recent news sentiment has been quite positive for SCNX, especially regarding FDA approval of their product SCN-102 and their strategic collaboration with KINDEVA DRUG DELIVERY. However, these news elements do not seem to have translated into positive price action yet. It is possible that the stock could witness a significant rebound in the future as the market digests these news while the company strategically prepares for the commercial product launch. Nonetheless, for the short-term, investors should brace for a potential further decline and watch the key support level for any potential shift in momentum.